Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Impact of Selinexor on AML Cell Lines and Healthy Donor T Cell Function: Enhanced Treg Cell Proportion

Xiwen Tong, Xiaojian Zhu, Su Shuai, Yi Zhu, Bin Xu, Yizhou Peng, Shiyuan Zhang, Jin Jie, Xia Mao, Jia Wei, Donghua Zhang

Blood (2024) 144 (Supplement 1): 5817.

https://doi.org/10.1182/blood-2024-205174

Published: 2024

Journal Articles

Efficacy and Safety of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Relapse/Refractory Non-Hodgkin's Lymphoma: Real-World Data in Chinese Population

Blood (2024) 144 (Supplement 1): 5115.

https://doi.org/10.1182/blood-2024-207186

Published: 2024

Journal Articles

The Expression of BTG1 in De Novo AML Patients Regulated By Demethylation of Decitabine and Its Evaluation in the Deep Remission of Patients

Shiyuan Zhang, Mengyuan Li, Xiaojian Zhu, Hao Zhou, Bin Xu, Xiwen Tong, Su Shuai, Yi Zhu, Yi Xiao, Liang Huang, Dengju Li, Wei Huang, Jia Wei, Mei Huang, Donghua Zhang

Blood (2024) 144 (Supplement 1): 1401.

https://doi.org/10.1182/blood-2024-205864

Published: 2024

Journal Articles

Efficacy of Decitabine in Combination with IA Versus IA in Patients with Newly Diagnosed AML, a Multicenter, Prospective, Randomized Controlled Trial

Xiwen Tong, Bin Xu, Shiyuan Zhang, Xiaojian Zhu, Mengyuan Li, Su Shuai, Yi Zhu, Zhenqian Huang, Yaya Wang, Yi Xiao, Liang Huang, Dengju Li, Wei Huang, Jia Wei, Mei Huang, Zhiping Huang, Yuanyan Tang, Hongbo Ren, Donghua Zhang

Blood (2024) 144 (Supplement 1): 4276.

https://doi.org/10.1182/blood-2024-205769

Published: 2024

Journal Articles

Real-World Experience with Selinexor -Containing Regimens in Post-Transplant AML/MDS Patients Who MRD Still Positive after First-Line Preemptive Treatment

Xiwen Tong, Shuai Su, Bin Xu, Xiaojian Zhu, Yizhou Peng, Jin Jie, Xia Mao, Min Xiao, Jay Mei, Donghua Zhang

Blood (2023) 142 (Supplement 1): 5837.

https://doi.org/10.1182/blood-2023-186006

Published: 2023

Journal Articles

Efficacy and Safety of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Relapse/Refractory Non-Hodgkin Lymphoma: Real-World Data in Chinese Population

Zixun Yan, Dehui Zou, Yuhua Li, Xiaojian Zhu, Dongmei Ji, Wenbin Qian, Ying Lu, Chunyan Ji, Keshu Zhou, Hongmei Jing, Hua Yang, Lanfang Li, Fei Li, Kailin Xu, Ting Niu, Depei Wu, Yu Hu, Weili Zhao

Blood (2023) 142 (Supplement 1): 6928.

https://doi.org/10.1182/blood-2023-181351

Published: 2023

Journal Articles

Improved Outcomes of All-Trans-Retinoic Acid and Arsenic Trioxide Plus Idarubicin As a Frontline Treatment in Adult Patients with Acute Promyelocytic Leukemia

Shiwei Yang, Zunmin Zhu, Xiaojian Zhu, Yicheng Zhang

Blood (2019) 134 (Supplement_1): 5088.

https://doi.org/10.1182/blood-2019-128602

Published: 2019

Journal Articles

The Interaction of Tumor Cells and Myeloid-Derived Suppressor Cells in Chronic Myelogenous Leukemia

Hui Xu, Zunmin Zhu, Xiaojian Zhu, Na Shen, Shu Zhou, Yicheng Zhang

Blood (2019) 134 (Supplement_1): 1636.

https://doi.org/10.1182/blood-2019-125563

Published: 2019

Journal Articles

Retrospective Analysis of Chinese Chronic Myeloid Leukemia Patients Who Have Stopped Tyrosine Kinase Inhibitors

Xiaojian Zhu, Yong You, PhD, Yicheng Zhang, MD PhD, Minghui Duan, MD, Yu Zhu, MD PhD, Bingcheng Liu, MD, Xin Du, MD, Suning Chen, PhD

Blood (2018) 132 (Supplement 1): 5443.

https://doi.org/10.1182/blood-2018-99-113854

Published: 2018

Journal Articles

Role of Folate Receptor 3 in Tyrosine Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia

Na Shen, Xiaojian Zhu, Shu Zhou, Yong You, PhD, Zhaodong Zhong, PhD, Xiaoying Zhu, Qing Li, PhD, Ping Zou, PhD, Yicheng Zhang, MD PhD

Blood (2018) 132 (Supplement 1): 2998.

https://doi.org/10.1182/blood-2018-99-111611

Published: 2018

Journal Articles

Correlation of Altered Expression of RIZ1 to Diagnosis, Risk Stratification, and Disease Progression in 56 Acute Leukemia Patients.

Qiubai Li, MD, Xiaojian Zhu, MD, Xiaoqing Li, PhD, Xiangjun Chen, Yong You, MD, Shi Huang, Shiang Huang, MD, Ping Zou, MD, Zhichao Chen

Blood (2009) 114 (22): 2627.

https://doi.org/10.1182/blood.V114.22.2627.2627

Published: 2009

NARROW

Impact of Selinexor on AML Cell Lines and Healthy Donor T Cell Function: Enhanced Treg Cell Proportion

Efficacy and Safety of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Relapse/Refractory Non-Hodgkin's Lymphoma: Real-World Data in Chinese Population

The Expression of BTG1 in De Novo AML Patients Regulated By Demethylation of Decitabine and Its Evaluation in the Deep Remission of Patients

Efficacy of Decitabine in Combination with IA Versus IA in Patients with Newly Diagnosed AML, a Multicenter, Prospective, Randomized Controlled Trial

Real-World Experience with Selinexor -Containing Regimens in Post-Transplant AML/MDS Patients Who MRD Still Positive after First-Line Preemptive Treatment

Efficacy and Safety of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Relapse/Refractory Non-Hodgkin Lymphoma: Real-World Data in Chinese Population

Improved Outcomes of All-Trans-Retinoic Acid and Arsenic Trioxide Plus Idarubicin As a Frontline Treatment in Adult Patients with Acute Promyelocytic Leukemia

The Interaction of Tumor Cells and Myeloid-Derived Suppressor Cells in Chronic Myelogenous Leukemia

Retrospective Analysis of Chinese Chronic Myeloid Leukemia Patients Who Have Stopped Tyrosine Kinase Inhibitors

Role of Folate Receptor 3 in Tyrosine Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia

Correlation of Altered Expression of RIZ1 to Diagnosis, Risk Stratification, and Disease Progression in 56 Acute Leukemia Patients.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only